What changed: Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma

Every dated change on the records linked to Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.